Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Establishment Labs Holdings (NASDAQ: ESTA) announced the publication of a study in Plastic and Reconstructive Surgery-Global Open, revealing that hybrid breast reconstruction using Motiva Ergonomix implants enhances outcomes compared to traditional methods. Analyzing 56 reconstructions in 33 patients, the findings highlighted improved control of breast shape and reduced complication risks. CEO Juan José Chacón-Quirós emphasized the commitment to innovative technology for better patient outcomes. It's important to note that these implants are not yet approved for commercial distribution in the U.S.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 2:00 PM ET. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will represent the company. The event will be available via live webcast on the Establishment Labs investor relations website, with an archived version accessible post-event. Establishment Labs specializes in women's health, focusing on breast aesthetics and reconstruction, and offers products like Motiva Implants®, available in over 80 countries.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) will announce its financial results for Q2 2020 on August 6, 2020, post-market. A conference call is scheduled for 5:30 PM ET to discuss these results. The company focuses on women's health, particularly in breast aesthetics and reconstruction, with a product range including the Motiva Implants® and the Divina® 3D Simulation System. Motiva Implants® have received FDA approval and are available in over 80 countries through various distribution channels.